SAN DIEGO, Sept. 01, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics (NASDAQ:CYTX) (“Cytori” or the “Company”) today announced a substantial corporate restructuring intended to significantly reduce expenses while maintaining its ability to execute on its BARDA-sponsored cell therapy program, Japanese business and oncology program. The Cytori Habeo program for scleroderma is expected to move forward based on feedback from its forthcoming meetings with the FDA in the U.S. and PMDA in Japan. The restructuring is expected to reduce Cytori’s workforce by approximately 50% and significantly reduce quarterly operational cash burn.
“Our need to conserve capital and focus our talented …
Read the full article at: http://www.nasdaq.com/press-release/cytori-announces-corporate-restructuring–cost-reduction-plan-20170901-00774